CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 235 enrolled
Drug / intervention
Secukinumab (AIN457)biological
Likely dose
Secukinumab (AIN457) 150mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01961609
NCT01961609Phase 3Completed
CompareCT.gov

Secukinumab In Patients With Moderate to Severe Active, Chronic Plaque Psoriasis Who Have Failed on TNFα antaGoNists: A Clinical Trial EvalUating Treatment REsults

Novartis Pharmaceuticals·interventional·Posted Oct 11, 2013·Updated Mar 18, 2019

In Brief

A Phase 3 clinical trial evaluating Secukinumab (AIN457) for Psoriasis. Completed, enrolled 235 participants across 54 sites in 2 countries.

Detailed Summary

This study was designed to prove and quantify the hypothesis that secukinumab is effective, safe and well tolerated in the treatment of moderate to severe chronic plaque-type psoriasis in patients who are inadequate responders to anti-TNFα therapy in a United Kingdom (UK) and Republic of Ireland) specific population.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPsoriasis
CountriesIreland, United Kingdom
Collaborators--

Timeline

Phase 3CompletedFinished
2014201520162017201820192020202120222023202420252026
First PostedOct 11, 2013
Enrollment StartOct 9, 2013
Primary CompletionJul 12, 2016
TodayJul 2, 2026
Enrollment to primary: 2.8 yearsPosted 12.7 years ago

Interventions

Secukinumab (AIN457)biological

Secukinumab was supplied in 150mg pre-filled syringes.